共查询到20条相似文献,搜索用时 31 毫秒
1.
AimSulfuretin, a major flavonoid isolated from Rhus verniciflua, is known to have anti-inflammatory effects. However, the mechanisms underlying the anti-inflammatory effect of sulfuretin on rheumatoid arthritis have not been elucidated. In this study we investigated whether sulfuretin treatment modulates the severity of arthritis in an experimental model.Main methodsWe evaluated the effects of sulfuretin on tumor necrosis factor-α (TNF-α)-treated human rheumatoid fibroblast-like synoviocytes (FLS) in vitro and on collagen-induced arthritis (CIA) mice in vivo.Key findingsIn vitro experiments demonstrated that sulfuretin suppressed the chemokine production, matrix metalloproteinase secretion, and cell proliferation induced by tumor necrosis factor-α in rheumatoid FLS. In addition, sulfuretin inhibited the osteoclast differentiation induced by macrophage colony-stimulating factor and receptor activator of NF-κB ligand in bone marrow macrophages. In mice with CIA, early intervention with sulfuretin prevented joint destruction, as evidenced by a lower cumulative disease incidence and an absence of diverse disease features based on hind paw thickness, radiologic and histopathologic findings, and inflammatory cytokine levels. In mice with established arthritis, sulfuretin treatment significantly reduced synovial inflammation and joint destruction. The in vitro and in vivo protective effects of sulfuretin were mediated by inhibition of the NF-κB signaling pathway.SignificanceThese results suggest that using sulfuretin to block the NF-κB pathway in rheumatoid joints reduces both inflammatory responses and joint destruction. Therefore, sulfuretin may have therapeutic value in preventing or delaying the progression of rheumatoid arthritis. 相似文献
2.
The window of opportunity is a concept critical to rheumatoid arthritis treatment. Early treatment changes the outcome of rheumatoid arthritis treatment, in that response rates are higher with earlier disease-modifying anti-rheumatic drug treatment and damage is substantially reduced. Axial spondyloarthritis is an inflammatory axial disease encompassing both nonradiographic axial spondyloarthritis and established ankylosing spondylitis. In axial spondyloarthritis, studies of magnetic resonance imaging as well as tumor necrosis factor inhibitor treatment and withdrawal studies all suggest that early effective suppression of inflammation has the potential to reduce radiographic damage. This potential would suggest that the concept of a window of opportunity is relevant not only to rheumatoid arthritis but also to axial spondyloarthritis. The challenge now remains to identify high-risk patients early and to commence treatment without delay. Developments in risk stratification include new classification criteria, identification of clinical risk factors, biomarkers, genetic associations, potential antibody associations and an ankylosing spondylitis-specific microbiome signature. Further research needs to focus on the evidence for early intervention and the early identification of high-risk individuals. 相似文献
3.
Interleukin-17 (IL-17) is a T cell cytokine spontaneously produced by cultures of rheumatoid arthritis (RA) synovial membranes. High levels have been detected in the synovial fluid of patients with RA. The trigger for IL-17 is not fully identified; however, IL-23 promotes the production of IL-17 and a strong correlation between IL-15 and IL-17 levels in synovial fluid has been observed. IL-17 is a potent inducer of various cytokines such as tumor necrosis factor (TNF)-alpha, IL-1, and receptor activator of NF-kappaB ligand (RANKL). Additive or even synergistic effects with IL-1 and TNF-alpha in inducing cytokine expression and joint damage have been shown in vitro and in vivo. This review describes the role of IL-17 in the pathogenesis of destructive arthritis with a major focus on studies in vivo in arthritis models. From these studies in vivo it can be concluded that IL-17 becomes significant when T cells are a major element of the arthritis process. Moreover, IL-17 has the capacity to induce joint destruction in an IL-1-independent manner and can bypass TNF-dependent arthritis. Anti-IL-17 cytokine therapy is of interest as an additional new anti-rheumatic strategy for RA, in particular in situations in which elevated IL-17 might attenuate the response to anti-TNF/anti-IL-1 therapy. 相似文献
4.
sTNFR-IgGFc融合基因在内皮细胞中的表达及其对小鼠关节炎模型的基因治疗研究 总被引:3,自引:1,他引:3
可溶性肿瘤坏死因子受体(sTNFR)可以拮抗肿瘤坏死因子的活性,因此已被用来治疗与TNF相关的炎性疾病。本研究将sTNFR与IgGFc片段的融合蛋白基因克隆到真核表达载体pStar上,转染到人的内皮细胞中,获得了表达。表达的sTNFR-IgGFc能够拮抗TNFα对L929细胞的细胞毒活性。将该质粒DNA与脂质体混合,经尾静脉注射到Ⅱ型胶原诱导的关节炎小鼠体内后,应用RT-PCR在鼠的肝脏检测到了sTNFR-IgGFc的表达,并显著地改善了治疗组小鼠关节炎症状和病理反应。这表明抗TNF基因治疗有可能作为治疗类风湿性关节炎的新的途径。 相似文献
5.
Gomes A Alam MA Bhattacharya S Dasgupta SC Mukherjee S Bhattacharya S Gomes A 《Indian journal of experimental biology》2011,49(8):565-573
Rheumatoid arthritis (RA) is one of the most common autoimmune disorder which causes swelling, redness, pain, stiffness, restriction of limb movements, decreases life expectancy and early death of the patients. Available drugs include non steroidal anti-inflammatory and analgesics, disease modifying anti-rheumatic drugs and steroids (glucocorticoids etc). All these drugs have their own limitations such as gastrointestinal irritations, cardiovascular problems, and drug dependency. Search for alternative therapy from natural products are being ventured throughout the world. Zoo therapy in arthritis, a common practice of the ancient times that have been mentioned in traditional and folk medicine. The scientific basis of some of the zoo products are being explored and have been showing promising results in experimental rheumatoid arthritis. These therapies have minimum side effects and many of them have potential to give rise to drug development clues against rheumatoid arthritis. The present review is an effort to establish the folk and traditional treatment of rheumatoid arthritis using zoo products. 相似文献
6.
Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis 总被引:4,自引:0,他引:4
Rheumatoid arthritis is a common autoimmune condition in which, for unknown reasons, synovial joints become the target of a sustained immune response. For many years, rheumatoid arthritis was in the 'too hard basket' in terms of understanding disease mechanisms and providing rational therapy. This has changed dramatically over the last 10 years and rheumatoid arthritis is now at the forefront of biotechnology. In this review, we outline one of the most exciting recent developments, namely antagonists of the cytokine TNF. The preclinical evaluation of TNF in animal models of rheumatoid arthritis, and subsequent clinical trials of TNF inhibitors in patients, provides insight into the 'bench to bedside' paradigm. We therefore briefly review rheumatoid arthritis, animal models of rheumatoid arthritis, the biology of TNF, the pivotal clinical trials of TNF antagonists and the emerging data on side-effects. Tumour necrosis factor inhibitors in rheumatoid arthritis represent the first attempt to achieve sustained blockade of a single cytokine in a human disease. Whilst this approach has been even more successful than might have been predicted, we suggest it is only the beginning of what has become a new therapeutic era. 相似文献
7.
The availability of agents that block the biological activity of tumor necrosis factor α (TNFα) in rheumatoid arthritis (RA)
has permitted studies that confirm the key role of this cytokine in the pathogenesis of this disease. To date, two anti-TNF
agents, infliximab and etanercept, have been approved for use in treatment. Clinical trials of these agents demonstrate efficacy
for the control of symptoms and signs and acceptable safety in patients who have failed to respond adequately to conventional
therapy. Combination with methotrexate appears to be particularly effective and may provide the main initial indication for
clinical application in the first instance. Repeated administration of anti-TNF therapies over a one year period results in
sustained reduction in symptoms and signs of RA in the majority of patients. It has recently become apparent that anti-TNF
therapy protects joints from structural damage. These findings imply that TNFα has a critical role in the bone and cartilage
damage associated with RA.
Evidence to date support the hypothesis that there are 2 particularly important mechanisms of action; deactivation of the
proinflammatory cytokine cascade at the site of inflammation and diminished recruitment of inflammatory cells from blood to
the rheumatoid joint. 相似文献
8.
A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn's disease. Crohn's disease is initiated by an innate immune response, which eventuates in a T-cell driven process, characterized by a T-helper cell 1 type cytokine profile. Several new treatments now focus on suppressing T-cell differentiation or T-cell inflammation. Since inflammatory bowel disease (IBD) represents a state of dysregulated inflammation, drugs that augment the anti-inflammatory response have the potential to downregulate inflammation and thereby hopefully modify the disease. Tumour necrosis factor (TNF) is a major target of research and clinical investigation. TNF has proinflammatory effects in the intestinal mucosa and is a pivotal cytokine in the inflammatory cascade. Certolizumab pegol (CDP870) is a PEGylated, Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody. PEGylation increases the half-life, reduces the requirement for frequent dosing, and possibly reduces antigenicity as well. Certolizumab has been shown in Phase III trials to achieve and maintain clinical response and remission in Crohn's disease patients. It improves the quality of life. Certolizumab pegol will be indicated for moderately to severely active Crohn's disease, but it is not yet licensed in Europe or the US. It is not possible to construct an algorithm for treatment, but when compared with infliximab the two principal advantages are likely to be lower immunogenicity (as shown by anti-drug antibodies, absence of infusion reactions, and low rate of antinuclear antibodies), and a subcutaneous route of administration. These two factors may be sufficient to promote it up the pecking order of anti-TNF agents. 相似文献
9.
Interleukin-17 (IL-17) is a T cell cytokine spontaneously produced by cultures of rheumatoid arthritis (RA) synovial membranes.
High levels have been detected in the synovial fluid of patients with RA. The trigger for IL-17 is not fully identified; however,
IL-23 promotes the production of IL-17 and a strong correlation between IL-15 and IL-17 levels in synovial fluid has been
observed. IL-17 is a potent inducer of various cytokines such as tumor necrosis factor (TNF)-α, IL-1, and receptor activator
of NF-κB ligand (RANKL). Additive or even synergistic effects with IL-1 and TNF-α in inducing cytokine expression and joint
damage have been shown in vitro and in vivo. This review describes the role of IL-17 in the pathogenesis of destructive arthritis with a major focus on studies in vivo in arthritis models. From these studies in vivo it can be concluded that IL-17 becomes significant when T cells are a major element of the arthritis process. Moreover, IL-17
has the capacity to induce joint destruction in an IL-1-independent manner and can bypass TNF-dependent arthritis. Anti-IL-17
cytokine therapy is of interest as an additional new anti-rheumatic strategy for RA, in particular in situations in which
elevated IL-17 might attenuate the response to anti-TNF/anti-IL-1 therapy. 相似文献
10.
Douglas James Veale 《Arthritis research & therapy》2013,15(6):224
Psoriatic arthritis (PsA) is the second most common inflammatory arthropathy, after
rheumatoid arthritis diagnosis, in early arthritis clinics. Most patients have
established psoriasis, often for years, prior to the onset of joint pain and
swelling; in addition, associated features of nail disease, dactylitis, enthesitis,
spondylitis or uveitis may be present. Psoriasis may not be immediately apparent, as
small or patchy lesions may occur in the scalp or perineum. PsA presents as a
symmetrical polyarthritis, similar to rheumatoid arthritis, or an asymmetrical
oligoarthritis with a predilection for the distal interphalangeal joints. Spinal
involvement is similar, although not identical, to ankylosing spondylitis. Joint
damage occurs early; up to 50% of PsA patients have an 11% annual erosion rate in the
first 2 years of disease duration, suggesting it is not a benign condition.
There have been significant advances in our understanding of PsA pathogenesis in
recent years, in the areas of genetics and molecular biology, implicating both the
innate and the adaptive immune systems. This has lead to the introduction of
evidence-based targeted therapy, primarily with tumour necrosis factor inhibitor
(TNFi) agents. Therapy with disease-modifying anti-rheumatic drugs, such as
methotrexate and leflunomide, remains the first-choice therapeutic intervention, even
though there are few randomised controlled trials with these agents. In contrast, a
number of successful studies of TNFi agents demonstrate excellent efficacy, in
combination with methotrexate, and several novel agents are currently in development
for the treatment of PsA. 相似文献
11.
Ronenn Roubenoff 《Arthritis research & therapy》2009,11(2):108
Rheumatoid cachexia, loss of muscle mass and strength and concomitant increase in fat mass, is very common in patients with
rheumatoid arthritis (RA). Despite great advances in the treatment of RA, it appears that rheumatoid cachexia persists even
after joint inflammation improves. Rheumatoid cachexia may be an important risk factor for cardiovascular disease and excess
mortality in RA. In this issue of Arthritis Research & Therapy, Elkan and colleagues demonstrate a link between rheumatoid cachexia and metabolic syndrome, further reinforcing the need
for therapy directed beyond inflammation and at the metabolic consequences of RA. 相似文献
12.
Proteolysis of the collagen fibril in osteoarthritis 总被引:1,自引:0,他引:1
Poole AR Nelson F Dahlberg L Tchetina E Kobayashi M Yasuda T Laverty S Squires G Kojima T Wu W Billinghurst RC 《Biochemical Society symposium》2003,(70):115-123
The development of cartilage pathology in osteoarthritis involves excessive damage to the collagen fibrillar network, which appears to be mediated primarily by the chondrocyte-generated cytokines interleukin-1 and tumour necrosis factor alpha and the collagenases matrix metalloproteinase-1 (MMP-1) and MMP-13. The damage to matrix caused by these and other MMPs can result in the production of sufficient degradation products that can themselves elicit further degradation, leading to chondrocyte differentiation and eventually matrix mineralization and cell death. Knowledge of these MMPs, cellular receptors and cytokine pathways, and the ability to selectively antagonize them by selective blockade of function, may provide valuable therapeutic opportunities in the treatment of osteoarthritis and other joint diseases involving cartilage resorption, such as rheumatoid arthritis. The ability to detect the products of these degradative events released into body fluids of patients may enable us to monitor disease activity, predict disease progression and determine more rapidly the efficacy of new therapeutic agents. 相似文献
13.
The availability of newer, and more expensive, therapies for patients with rheumatoid arthritis has changed treatment beyond
recognition. Disease remission is the goal for all new patients. Studies have shown that a combination of tumour necrosis
factor (TNF)-blocking drugs and methotrexate produces superior outcomes over monotherapy alone; however, use is limited by
cost and potential side-effects. Currently, anti-TNF therapy is normally reserved for patients who have failed traditional
disease-modifying anti-rheumatic drugs. The question that remains is whether TNF-blocking drugs are better used if given early;
the high direct costs are countered by both direct and indirect savings in healthcare costs from optimal control of disease,
and the benefits of early control outweigh the increased risk of infection and malignancy. 相似文献
14.
The availability of newer, and more expensive, therapies for patients with rheumatoid arthritis has changed treatment beyond recognition. Disease remission is the goal for all new patients. Studies have shown that a combination of tumour necrosis factor (TNF)-blocking drugs and methotrexate produces superior outcomes over monotherapy alone; however, use is limited by cost and potential side-effects. Currently, anti-TNF therapy is normally reserved for patients who have failed traditional disease-modifying anti-rheumatic drugs. The question that remains is whether TNF-blocking drugs are better used if given early; the high direct costs are countered by both direct and indirect savings in healthcare costs from optimal control of disease, and the benefits of early control outweigh the increased risk of infection and malignancy. 相似文献
15.
Anja Strangfeld Franka Hierse Rolf Rau Gerd-Ruediger Burmester Brigitte Krummel-Lorenz Winfried Demary Joachim Listing Angela Zink 《Arthritis research & therapy》2010,12(1):R5
Introduction
We used the data of the German biologics register RABBIT, a nationwide prospective cohort study, to investigate the risk of new or recurrent malignancy in patients with rheumatoid arthritis (RA) receiving biologics compared to conventional disease modifying anti-rheumatic drugs (DMARDs). 相似文献16.
Tumour necrosis factor alpha (TNF-alpha) is a pro-inflammatory cytokine with pleiotropic activity that binds to two transmembrane receptors. Its role in mediating the inflammatory response to injury or infection has been well documented and it has been shown to be a causative factor in rheumatoid arthritis, inflammatory bowel disease and septic shock. Using synthetic peptide libraries composed exclusively of D-amino acids, two distinct hexapeptide families that block the binding of TNF-alpha to its receptors were identified. In the deconvolution of the library, activity increased from submillimolar to the low micromolar range with the most active compound having an IC50 of 0.33 microM. With the aid of biotinylated constructs of these hexapeptides it was possible to demonstrate that their antagonistic effect is due to specific binding to TNF-alpha and not to its receptor. 相似文献
17.
van Holten J Reedquist K Sattonet-Roche P Smeets TJ Plater-Zyberk C Vervoordeldonk MJ Tak PP 《Arthritis research & therapy》2004,6(3):R239-R249
We investigated the therapeutic potential and mechanism of action of IFN-beta protein for the treatment of rheumatoid arthritis (RA). Collagen-induced arthritis was induced in DBA/1 mice. At the first clinical sign of disease, mice were given daily injections of recombinant mouse IFN-beta or saline for 7 days. Disease progression was monitored by visual clinical scoring and measurement of paw swelling. Inflammation and joint destruction were assessed histologically 8 days after the onset of arthritis. Proteoglycan depletion was determined by safranin O staining. Expression of cytokines, receptor activator of NF-kappaB ligand, and c-Fos was evaluated immunohistochemically. The IL-1-induced expression of IL-6, IL-8, and granulocyte/macrophage-colony-stimulating factor (GM-CSF) was studied by ELISA in supernatant of RA and osteoarthritis fibroblast-like synoviocytes incubated with IFN-beta. We also examined the effect of IFN-beta on NF-kappaB activity. IFN-beta, at 0.25 microg/injection and higher, significantly reduced disease severity in two experiments, each using 8-10 mice per treatment group. IFN-beta-treated animals displayed significantly less cartilage and bone destruction than controls, paralleled by a decreased number of positive cells of two gene products required for osteoclastogenesis, receptor activator of NF-kappaB ligand and c-Fos. Tumor necrosis factor alpha and IL-6 expression were significantly reduced, while IL-10 production was increased after IFN-beta treatment. IFN-beta reduced expression of IL-6, IL-8, and GM-CSF in RA and osteoarthritis fibroblast-like synoviocytes, correlating with reduced NF-kappaB activity. The data support the view that IFN-beta is a potential therapy for RA that might help to diminish both joint inflammation and destruction by cytokine modulation. 相似文献
18.
Hiroki Tawaratsumida Takao Setoguchi Yoshiya Arishima Hideo Ohtsubo Masaki Akimoto Yasuhiro Ishidou Satoshi Nagano Eiji Taketomi Nobuhiko Sunahara Setsuro Komiya 《BMC research notes》2017,10(1):765
Objective
Osteoporosis is a complication of rheumatoid arthritis. We examined the risk factors for bone loss in rheumatoid arthritis patients receiving biological disease-modifying anti-rheumatic drugs. Lumbar spine and femoral neck bone mineral density was measured at two time points in 153 patients with rheumatoid arthritis managed with biological disease-modifying anti-rheumatic drugs. We examined patients’ variables to identify risk factors for least significant reduction of bone mineral density.Results
Least significant reduction of lumbar spine bone mineral density (≤ ? 2.4%) was seen in 13.1% of patients. Least significant reduction of femoral neck bone mineral density (≤ ? 1.9%) was seen in 34.0% of patients. Multiple logistic regression analysis showed that a risk factor for least significant reduction of the lumbar spine was high-dose methylprednisolone use. Multiple regression analysis showed that a risk factor for least significant reduction of the femoral neck was short disease duration. Our findings showed that a risk factor for femoral neck bone mineral density reduction was a short disease duration. These findings suggest that rheumatoid arthritis patients receiving treatment with biological disease-modifying anti-rheumatic drugs may benefit from earlier osteoporosis treatments to prevent femoral neck bone loss.19.
Background: Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine involved in certain inflammatory diseases including multiple sclerosis (MS), rheumatoid arthritis (RA), and Crohn’s disease. The anti-TNF-α treatments used for RA may be associated with inflammatory demyelinating events affecting the central nervous system and may possibly aggravate known MS. Objective: We report here three new cases of inflammatory demyelinating events of the central nervous system following treatment with anti-TNF-α. Results: The neurological symptoms appeared on average 5 months after initiation of the treatment. For all patients, the inflammatory process was confirmed by brain magnetic resonance imaging. The symptoms totally or partially regressed as soon as anti-TNF-α treatment was stopped except for one patient who developed clinically defined MS. Conclusions: Inflammatory demyelination of the central nervous system may be associated with the use of anti-TNF-α. Patients with rheumatoid arthritis treated with these treatments should benefit from a follow-up which includes brain MRI. 相似文献
20.
Kalden JR 《Arthritis research》2002,4(Z2):S34-S40
Tumor necrosis factor alpha (TNF-alpha) is an inflammatory cytokine that has been implicated in a variety of rheumatic and inflammatory diseases. New understanding of the importance of TNF-alpha in the pathophysiology of rheumatoid arthritis and Crohn's disease led to the development of a new class of targeted anti-TNF therapies. Anti-TNF-alpha agents including etanercept (a fusion protein of the p75 TNF receptor and IgG1) and infliximab (a chimeric monoclonal antibody specific for TNF-alpha) have been approved for the treatment of rheumatoid arthritis. In addition, infliximab has been approved in the treatment of patients with active or fistulating Crohn's disease. A new appreciation of the importance of TNF-alpha in other rheumatic and inflammatory diseases has led to a broadening of the application of anti-TNF agents. Both etanercept and infliximab have been used in open-label and randomized studies in patients with psoriatic arthritis. Although larger randomized trials are needed to confirm early results, both these anti-TNF-alpha agents, etanercept and infliximab, have demonstrated activity in improving the signs and symptoms of psoriatic arthritis and psoriasis. Infliximab has also been shown to be effective in patients with other rheumatic diseases, including ankylosing spondylitis, and may be effective in adult-onset Still's disease, polymyositis, and Beh?et's disease. Further investigations will fully elucidate the role of infliximab in these and other rheumatic diseases. 相似文献